Category: Pricing

August 30, 2023

The Biden administration has picked the first 10 high-priced prescription drugs subject to federal price negotiations, taking a swipe at the powerful pharmaceutical industry. It marks a major turning point in a long-fought battle to control ever-rising drug prices for […]

August 1, 2023

The acquisition is a quiet end for EQRx, which was launched three years ago by biotech venture capitalist Alexis Borisy and quickly became one of the sector’s most closely watched startups. EQRx formed with an unusual mission to develop lower-cost […]

July 19, 2023

The U.S. has long been the most lucrative market for pharmaceutical makers, in part because there are no mechanisms such as price negotiations to control the cost of medicines. As a result, Americans pay more than three times as much […]

February 8, 2023

President Biden doubled down on efforts to rein in prescription drug prices during his State of the Union address on Tuesday and warned Republicans that he will fight any attempts to roll back his initiatives. Biden called on lawmakers to […]

January 17, 2023

The companies will now come under the alternative statutory scheme imposed by the government through law, demonstrating what the ABPI describes as ‘the depth of feeling that the current voluntary scheme is damaging the UK life sciences industry’. Introduced in […]

January 13, 2023

The lawsuit also takes aim at the three largest pharmacy benefit managers (PBMs) in the US – CVS Caremark, Express Scripts, and OptumRx – which are accused of adopting a system of rebates that incentivise manufacturers to raise list prices […]

January 9, 2023

The US regulator has granted accelerated approval to anti-amyloid therapy Leqembi (lecanemab) with a fairly broad label to treat patients in the mild cognitive impairment or mild dementia stage of disease who have confirmed presence of amyloid pathology. Eisai and […]

December 14, 2022

The Biden administration is facing mounting pressure from states to let them import medicine from Canada to help lower prescription drug costs. Colorado on Dec. 5 became at least the fourth state to seek federal permission to use the strategy, […]

December 7, 2022

Pricing and market access in France operate on a dual system, under which health technology assessments (HTAs) are conducted separately from pricing negotiations. The HTA body, the CT (Commission de la Transparence – Transparency Commission), is charged with providing guidance […]

November 21, 2022

The company argues that the cost is justified as Tzield (teplizumab) is the first drug that can delay the onset of type 1 diabetes, fending off the time when they become highly reliant on insulins and at risk of the […]

October 24, 2022

For over two years now, the US government has been running its public vaccination campaign – the largest in American history – and has purchased all of the Covid vaccines administered in the States, including over 500 million doses from […]

October 3, 2022

Amylyx Pharmaceuticals’ Relyvrio – a new treatment for amyotrophic lateral sclerosis (ALS) approved by the FDA on Thursday, after review of the data from its phase 2 trial – was the next day set at a list price of $158,000 […]

August 15, 2022

The pharmaceutical industry is gearing up to minimize the effect of major drug legislation passed by Congress on Friday, the first time in many years lawmakers have overcome the drug lobby’s opposition to limits on their pricing power. On Friday, […]

July 25, 2022

A snappy political advertisement from the conservative advocacy group American Commitment bluntly charges Sen. Joe Manchin (D-W.Va.) with supporting a legislative plan that would drain “billions in funds” from Medicare. Specifically, the ad claims that Manchin and AARP, the well-known advocacy group for people […]

July 22, 2022

The CMA delivered a preliminary judgment in the case last year which concluded that Pfizer and Flynn abused a dominant position in phenytoin sodium capsules, causing NHS spending on the drug to balloon from around £2 million a year in 2012 to […]

July 6, 2022

An ounce of prevention … well, you know the rest. In medicine, prevention aims to spot problems before they worsen, affecting both a patient’s health and finances. One of the more popular parts of the Affordable Care Act, which allows […]

May 31, 2022

Despite a long history of difficulties in this area, FDA once again is taking steps to facilitate the import of less costly prescription drugs from Canada by states, Indian Tribes, and other entities. The Canadian government has objected to the […]

March 23, 2022

Senate Majority Leader Chuck Schumer said yesterday that a vote on legislation which would introduce the cap – already backed in a House of Representatives vote last November – would take place this spring after the April recess. If passed, […]

February 4, 2022

Decision makers in the healthcare industry including payers, especially those who rely on the use of cost-effectiveness analysis (CEA) to evaluate new drugs, are often criticised for failing to capture the holistic value of drugs in their health technology assessments […]

December 20, 2021

The price reduction for Aduhelm (aducanumab) comes into play from 1 January and comes on the back of the “feedback of our stakeholders,” said the biotech’s chief executive Michel Vounatsos. “Too many patients are not being offered the choice of […]